• HLB Pharmaceutical set a KRW 55 billion investment to expand production capacity at its Hyangnam GMP plant.
• Project targets upgrades to aging equipment, plant expansion, stable manufacturing base.
• Spending equals 43.95% of equity, based on its 2025 consolidated financial statements.
• Construction timeline runs from Oct. 1, 2026 to Jan. 31, 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HLB Pharmaceutical Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261001900652), on October 01, 2026, and is solely responsible for the information contained therein.